Click here for slides on this topic


Myocardial infarction

A form of heart attack. In myocardial infarction (MI), there is necrosis of a portion of the heart muscle usually due to coronary artery obstruction.
The following content matched the glossary term: Myocardial infarction

T195-04

Top

Patient education handout exploring the connection between diabetes and cardiovascular disease.

Association between intensification of metformin treatment with insulin vs sulfonylureas and CV events and all-cause mortality among patients with diabetes

Top

Roumie CL, Greevy RA, Grijalva CG, et al. Association between intensification of metformin treatment with insulin vs sulfonylureas and cardiovascular events and all-cause mortality among patients with diabetes. JAMA. 2014;311(22):2288-2296.

Impact of specific glucose-control strategies on microvascular and macrovascular outcomes in 58,000 adults with type 2 diabetes

Top

Neugebauer R, Fireman B, Roy JA, O’Connor PJ. Impact of specific glucose-control strategies on microvascular and macrovascular outcomes in 58,000 adults with type 2 diabetes. Diabetes Care. 2013;36:3510-3516.

Changes in diabetes-related complications in the United States, 1990–2010

Top

Gregg EW, Li Y, Wang J, et al. Changes in diabetes-related complications in the United States, 1990–2010. N Engl J Med. 2014;370:1514-1523.

Glycated hemoglobin measurement and prediction of cardiovascular disease

Top

The Emerging Risk Factors Collaboration. Glycated hemoglobin measurement and prediction of cardiovascular disease. JAMA. 2014;311(12):1225-1233.

Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus

Top

Lincoff AM, Tardiff J-C, Schwartz GG, et al; for the AleCardio Investigators. Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus. The AleCardio randomized clinical trial. JAMA.. 2014. doi:10.1001/jama.2014.3321.

Clinical Insights in Diabetes Newsletter October 2013

Top

Clinical Insights® in Diabetes newsletter October 2013

Exploring DPP-4 CV safety in SAVOR-TIMI 53 and EXAMINE, CV outcomes in Look AHEAD, relationship between gastric bypass and A1C and cardiometabolic risk factors, metabolic effects of bariatric surgery and medical therapy in STAMPEDE, statin use and diabetes risk, severe hypoglycemia and CVD disease risk.

Alogliptin after acute coronary syndrome in patients with type 2 diabetes

Top

White WB, Cannon CP, Heller SR, et al for the EXAMINE Investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369(14):1327-1335.

1 2 3 4 5 6 7 8 9 10  ... Next 

Slide Library Results

Search Results for: Myocardial infarction Slides Found: 213
Incidence of Type 2 Diabetes-Related Vascular Disease in Four Ethnic Groups
Diabetes and Post-MI Survival in Two Ethnic Groups
Results From Statin Trials for Patients With Diabetes
Pioglitazone Decreases Carotid IMT Independent of Glycemic Control in Patients With Type 2 Diabetes
ALLHAT: Clinical Outcomes in Antihypertensive Treatments
DIGAMI 2: Cumulative Mortality After Acute MI in Type 2 Diabetes
PROactive: Objective/Endpoints
PROactive: Time to Primary Composite Endpoint
INTERHEART: Waist-to-Hip Ratio Is a Better Predictor for MI Than BMI
DCCT/EDIC: Incidence of Nonfatal MI, Stroke, or Death
TNT: Intensive Atorvastatin Treatment Reduces Cardiovascular Events in Patients With CHD and Diabetes
Microalbuminuria Predicts CV Risk at Levels Below Current Definition
East-West Study: 7-Year Incidence of Fatal and Nonfatal MI in Type 2 Diabetes and CHD
Cardiovascular Impact of Pioglitazone Therapy: A Meta-analysis
Long-term Risk of Myocardial Infarction With Rosiglitazone: A Meta-analysis
Long-term Risk of Heart Failure With Rosiglitazone: A Meta-analysis
Long-term Risk of Cardiovascular Mortality With Rosiglitazone: A Meta-analysis
Pioglitazone Reduces the Risk of Hospitalization for AMI
Steno-2: Effect of Multifactorial Intervention on CV Events in Type 2 Diabetes
ACCORD: Study Design
ACCORD: Results
ACCORD Trial: Intensive Blood Glucose Control in Patients With Type 2 Diabetes
ACCORD Trial: CV Events With Intensive Blood Glucose Control
UKPDS: Intensive SU-Insulin vs Conventional Therapy: Myocardial Infarction
UKPDS: Intensive Metformin vs Conventional Therapy: Myocardial Infarction
POPADAD Trial: Causes of Death in Patients With Diabetes According to
POPADAD Trial: Effect of Antioxidant Use on Events in Patients With Diabetes
POPADAD Trial: Effect of Aspirin Use on Events in Patients With Diabetes
PROactive 10 Substudy: Time to CV Death, Nonfatal MIa, Nonfatal Stroke
PROactive 10 Substudy: Time to All-Cause Mortality, Nonfatal MIa, Nonfatal Stroke, or ACS
VADT: Comparing Intensive With Standard Glucose Therapy, Primary Outcome
HEART2D: Primary Outcome Vs Days in Trial by Treatment Strategy
HEART2D Trial: A1C Values at Each Visit for 60 Months
Odds Ratios of In-Hospital Mortality by Admission and Fasting Glucose Levels
Mortality Risk Up to 6-Months in Patients With or Without Diabetes
Death At 30 Days By Average In-Hospital Glucose Level
RECORD: Conclusion
Meta-Analysis: Intensive vs Standard Glucose Treatment on A1C Concentration at Follow-Up
Meta-Analysis: Intensive vs Standard Glucose Treatment on Non-Fatal Myocardial Infarc
Meta-Analysis: Intensive vs Standard Glucose Treatment on CHD
Meta-Analysis: Conclusion
ACCORD: A1C and Mortality Risk
ACCORD: Annual Incidence of Hypoglycemia in the Intensive Versus Standard Treatment Groups
ACCORD: Hypoglycemia and Mortality
VADT: Primary Endpoint
Risk of Cardiovascular Events During Treatment with Pioglitazone or Rosiglitazone: Design
Risk of Cardiovascular Events During Treatment with Pioglitazone or Rosiglitazone: Composite Outcome
ACCORD LIPID: Effects of Combination Statin + Fibrate Therapy
ACCORD LIPID: Effects of Combination Statin + Fibrate Therapy
ACCORD BP: Effects of Intensive BP-Control on Type 2 Diabetes
ACCORD BP: Effects of Intensive BP-Control on Type 2 Diabetes
ACCORD Substudy: Impact of Frequent and Unrecognized Hypoglycemia on Mortality—Design
ORIGIN Glargine Trial: Eligibility Criteria and Trial Profile
ORIGIN Omega-3 Fatty Acid Trial: Eligibility Criteria and Trial Profile
ORIGIN Omega-3 Fatty Acid Trial: Baseline Characteristics (1 of 2)
ORIGIN Omega-3 Fatty Acid Trial: Baseline Characteristics (2 of 2)
Vascular Risk Associated with Medication-Related Hypoglycemia: Design
Cumulative Incidence of CVD: Hypoglycemia Group vs Control
Cumulative Incidence of Microvascular Complications: Hypoglycemia Group vs Control
Medical Comorbidities Associated with Obesity
JUPITER: Design
JUPITER Analysis: Design
JUPITER: Statin Therapy for Primary Prevention of Cardiovascular Disease—Rationale
JUPITER: Study Design
JUPITER Results: Primary Endpoint
JUPITER Results: Components of Primary Endpoint
Pooled Analysis: Mortality Among Normal and Overweight/Obese Subjects with Diabetes
Pooled Analysis: Mortality Rates Among Normal and Overweight/Obese Subjects with Diabetes
ADA/AGS 2012 Consensus Report on Diabetes in Older Adults: Key Facts on Prevalence, Epidemiology
Meta-analysis: Effects of DPP-4 Inhibitors on CV Events Design
Meta-analysis: Effects of DPP-4 Inhibitors on CV Events Results for Primary Endpoint
SOS Post-hoc Analysis: Effect of Bariatric Surgery on CV Events
SOS Post-hoc Analysis: MI in Obese Subjects with Type 2 Diabetes
SOS Post-hoc Analysis: Stroke in Obese Subjects with Type 2 Diabetes
Diabetic Retinopathy and Incident CV Events in ACCORD: Results
Diabetes Heart Study: CAC and CVD Mortality
PREDIMED: Mediterranean Diet for Primary Prevention of CVD
PREDIMED: Primary Endpoint Rate
PREDIMED: Secondary Endpoint Events
PREDIMED: Primary Endpoint Events
ACCORD: Death from Any Cause
HPS2-THRIVE: Niacin +Laropiprant for Vascular Risk Reduction
HPS2-THRIVE: Baseline Characteristics
CHAMPION PHOENIX: Randomization
CHAMPION PHOENIX: Ischemic Endpoints
CHAMPION PHOENIX: Baseline Characteristics
CHAMPION PHOENIX: Rate of the Primary Efficacy Endpoint
CHAMPION PHOENIX: Rate of the Primary Efficacy Endpoint at 30 Days
AIM-HIGH: Design
AIM-HIGH: Baseline Characteristics
AIM-HIGH: Rate of the Primary Endpoint
AIM-HIGH: Rate of Secondary Endpoints
ORIGIN-GRACE: Major Cardiovascular Events
Risk and Prevention Study: Design
Risk and Prevention Study: Secondary Endpoints
ORIGIN-GRACE: Eligibility Criteria and Trial Profile
ESH/ESC Hypertension Guidelines: Hypertension Treatment for Clinical CV Event
ESH/ESC Hypertension Guidelines: Hypertension Treatment for Patients With Heart Disease
ESH/ESC Hypertension Guidelines: Hypertension Treatment for Patients With Atherosclerosis, Arteriosclerosis, and PAD
Look AHEAD: No Reduction in CV Events with Lifestyle Changes
Look AHEAD: No Reduction in Secondary CV Outcomes with Lifestyle Changes
Look AHEAD: Primary Outcome, Participant Characteristics
BP Rates and All-Cause Mortality in Newly Diagnosed Type 2 Diabetes: Design
BP Rates and All-Cause Mortality in Newly Diagnosed Type 2 Diabetes: Results
Meta-Analysis: Risk for New-Onset Diabetes and CV Events with Intensive- Vs Moderate Dose Statins
Meta-Analysis: New-Onset Diabetes and CV Events With Intensive- Vs Moderate-Dose Statins
Meta-Analysis: New-Onset Diabetes With Intensive- Vs Moderate-Dose Statins
Meta-Analysis: CV Events With Intensive- Vs Moderate-Dose Statins
ALTITUDE: No Reduction in CV, Renal Events with Aliskiren
ONTARGET: Similar CV Outcomes with Ramipril, Telmisartan, and Their Combination
SAVOR-TIMI 53: No Increase in CV Events with Saxagliptin in Patients With or At Risk for CVD Secondary Endpoint
SAVOR-TIMI 53: Saxagliptin Increased Hospitalization for Heart Failure
SAVOR-TIMI 53: Significantly Better Glycemic Control with Saxagliptin
SAVOR-TIMI 53: Safety Endpoints
SAVOR-TIMI 53: Design
Metformin: Renal Considerations
EXAMINE: No Increase in CV Events with Alogliptin Primary Endpoint
EXAMINE: No Increase in CV Events with Alogliptin Secondary Endpoint
EXAMINE: Adverse Events
EXAMINE: Design
ACC/AHA Cholesterol Guidelines 2013: Statin Benefit Groups for ASCVD Prevention
ACC/AHA Cholesterol Guidelines 2013: ASCVD Statin Benefit Group 1: Secondary Prevention
ACC/AHA Cholesterol Guidelines 2013: ASCVD Statin Benefit Group 1: Primary Prevention LDL-C 190 or Higher
ACC/AHA Cholesterol Guidelines 2013: ASCVD Statin Benefit Group 3: Primary Prevention Diabetes
ACC/AHA Cholesterol Guidelines 2013: ASCVD Statin Benefit Group 4: Primary Prevention With 10-Yr ASCVD Risk 7.5% or Higher (No Diabetes)
ACC/AHA Cholesterol Guidelines 2013: The Argument Against LDL-C, Non-HDL-C Targets
ACC/AHA Cholesterol Guidelines 2013: Role of Biomarkers & Imaging Tests
ACC/AHA Cholesterol Guidelines 2013: LDL-C, Non-HDL-C Targets
ACC/AHA Cholesterol Guidelines 2013: Statin Therapy for Secondary Prevention
ACC/AHA Cholesterol Guidelines 2013: Statin Therapy for Primary Prevention: LDL-C 190 or Higher
ACC/AHA Cholesterol Guidelines 2013: Statin Therapy for Primary Prevention: Diabetes & LDL-C 70-189
ACC/AHA Cholesterol Guidelines 2013: Statin Therapy for Primary Prevention: LDL-C 70-189, No Diabetes
ACC/AHA Cholesterol Guidelines 2013: Heart Failure and Hemodialysis
ACC/AHA Cholesterol Guidelines 2013: High-Intensity Statin for Secondary ASCVD Prevention
ACC/AHA Cholesterol Guidelines 2013: Secondary ASCVD Prevention for Age >75 Years
ACC/AHA Cholesterol Guidelines 2013: Statin Initiation for Secondary Prevention: Age 75 Years or Younger
ACC/AHA Cholesterol Guidelines 2013: Statin Initiation for Secondary Prevention: Age 75 and Older
ACC/AHA Cholesterol Guidelines: Primary ASCVD Prevention for LDL-C 190 or Higher
ACC/AHA Cholesterol Guidelines 2013: Statin Initiation for Primary ASCVD Prevention: Age 40-75 With Diabetes or LDL 190 or Higher
ACC/AHA Cholesterol Guidelines 2013: Statin Initiation for Primary ASCVD Prevention: Age 40-75, LDL 70-189, No Diabetes
ACC/AHA Cholesterol Guidelines 2013: Primary ASCVD Prevention in Individuals With Diabetes
ACC/AHA Cholesterol Guidelines 2013: Primary ASCVD Prevention in Individuals With 70-189, No Diabetes
ACC/AHA Cholesterol Guidelines 2013: Primary ASCVD Prevention for Individuals Not in A Statin Benefit Group
ACC/AHA Cholesterol Guidelines 2013: 10-Yr ASCVD Risk Assessment Calculator: Primary Prevention
ACC/AHA Cholesterol Guidelines 2013: Statin Safety Recommendations: Maximizing Statin Safety
ACC/AHA Cholesterol Guidelines 2013: Statin Safety Recommendations: CK & ALT
ACC/AHA Cholesterol Guidelines 2013: Statin Safety Recommendations: Statin Dosing
ACC/AHA Cholesterol Guidelines 2013: Statin Safety Recommendations: Muscle Symptoms
ACC/AHA Cholesterol Guideline 2013: Statin Safety Recommendations: Cognitive Impairment
ACC/AHA Cholesterol Guidelines 2013: Nonstatin Safety Recommendations: Niacin
ACC/AHA Cholesterol Guidelines 2013: Nonstatin Safety Recommendations: Bile-Acid Sequestrants & Ezetimibe
ACC/AHA Cholesterol Guidelines 2013: Nonstatin Safety Recommendations: Fibrates
ACC/AHA Cholesterol Guidelines 2013: Nonstatin Safety Recommendations: Omega-3 Fatty Acids
ACC/AHA Cholesterol Guidelines 2013: Guidance on Nonstatin Therapies
ACC/AHA Cholesterol Guidelines 2013: Monitoring & Optimizing Statin Therapy
ACC/AHA Cholesterol Guidelines 2013: Insufficient Response to Statin Therapy
US Adults Diagnosed Diabetes | Diabetes Slides | NDEI
Diabetes Complications Decreased in US | Diabetes Slides | NDEI
Diabetes Complications in US Diagnosed or Undiagnosed | NDEI
Diabetes Complications Relative Risks US Adults | NDEI
Type 2 Diabetes Treatment Intensification Micro- Macrovascular | NDEI
Type 2 Diabetes Treatment Intensification Acute MI | NDEI
Type 2 Diabetes Treatment Intensification Albuminuria | NDEI
Type 2 Diabetes Treatment Intensification eGFR Kidney | NDEI
ACC/AHA Cholesterol Guidelines 2013: Estimated 10-Yr ASCVD Risk Guides Statin Therapy
Insulin Sulfonlyrea Added to Metformin CVD Mortality | NDEI
Metformin + Insulin or Sulfonylurea CVD Mortality | NDEI
Metformin + Insulin or Sulfonylurea CVD Mortality Design | NDEI
JNC 8 Guidelines First-Line Antihypertensive Therapy PPT | NDEI
SAVOR TIMI Saxagliptin Pancreatitis | NDEI
SAVOR TIMI 53 Pancreatitis Risk Factors Saxagliptin DPP-4 | NDEI
No Pancreatic Cancer Signal Saxagliptin DPP-4 SAVOR TIMI | NDEI
SAVOR TIMI 53 Pancreatitis Cancer Saxagliptin DPP-4 | NDEI
Statin Potency New-Onset Diabetes Risk | NDEI
Statin Potency & Type 2 Diabetes Risk | NDEI
High-Potency Statins & Increased Diabetes Risk Secondary Prevention | NDEI
Rosiglitazone Cardiovascular Risk RECORD Slides | NDEI
RECORD Rosiglitazone Cardiovascular Effects Slides | NDEI
Higher CV Risk With Metformin + Sulfonylurea Vs DPP-4 Inhibitor | NDEI
Edinburgh Type 2 Diabetes Study Severe Hypoglycemia Slide PPT | NDEI
Edinburgh Type 2 Diabetes Hypoglycemia Linked to Macrovascular Death Slides PPT | NDEI
ADVANCE-ON Type 2 Diabetes Primary Outcomes Intensive Glucose Slide | NDEI
TECOS Sitagliptin Cardiovascular Safety High-Risk Type 2 Diabetes DPP-4 | NDEI
TECOS Cardiovascular Outcomes Sitagliptin DPP-4 | NDEI
Efficacy and Safety of Saxagliptin in Older Adults in SAVOR-TIMI 53
No Increased Ischemic Events With Saxagliptin Vs Placebo in Older Adults in SAVOR-TIMI 53
Mean A1C Reduction With Saxagliptin in Older Adults in SAVOR-TIMI 53
IMPROVE-IT Ezetimibe Simvastatin Reduces CV Events Type 2 Diabetes | NDEI
Ezetimibe/Simvastatin Reduces MI & Stroke Type 2 Diabetes IMPROVE-IT | NDEI
Combo Ezetimibe/Simvastatin LDL-C Type 2 Diabetes IMPROVE-IT | NDEI
SAVOR-TIMI 53: No Increase in CV Events with Saxagliptin in Patients With or At Risk for CVD
EMPA-REG OUTCOME Empagliflozin CV Death Reduced Type 2 Diabetes | NDEI
Empagliflozin Reduces Death Type 2 Diabetes EMPA-REG OUTCOME EASD | NDEI
Insulin Glargine Neutral on CV Outcomes & Cancer Diabetes ORIGIN | NDEI
Neutral Omega-3 Effect on CV Outcomes in ORIGIN Diabetes | NDEI
ACCELERATE Evacetrapib Does Not Lower CV Events in High-Risk Patients | NDEI
ACCELERATE Evacetrapib Doubles HDL-C & Lowers LDL-C CETP | NDEI
ACCELERATE CETP Inhibitor Trial Ended Early Due to Futility
HOPE-3 CV Event Reduction With Rosuvastatin Vs Placebo PPT | NDEI
HOPE-3 CV Event Reduction With Antihypertensive Therapy PPT | NDEI
HOPE-3 Lipid- & BP-Lowering Intermediate Risk CV Events PPT | NDEI
ORIGINALE No Increase in CV Events or Cancer with Insulin Glargine Diabetes | NDEI
ORIGINALE No Effect of Omega-3 Fatty Acids on CV Outcomes | NDEI
SAVOR-TIMI 53 Saxagliptin Not Associated With Fracture Risk Diabetes | NDEI
LEADER Design Cardiovascular Safety Study Liraglutide CVOT PPT | NDEI
Liraglutide Reduced CV Events in LEADER CV Outcomes Trial PPT | NDEI
Liraglutide Cardiovascular Outcomes Trial LEADER Heart Failure PPT | NDEI
Empagliflozin Reduces Kidney Disease in EMPA-REG OUTCOME CVOT | NDEI
Empagliflozin Renal Outcomes in EMPA-REG OUTCOME CVOT | NDEI
IRIS Design Pioglitazone Effect on Cerebrovascular Disease Stroke PPT | NDEI
IRIS Pioglitazone Lowers Risk for Stroke and TIA Vs Placebo PPT | NDEI
IRIS Pioglitazone Lowers Rate of Progression to Diabetes Vs Placebo | NDEI
IRIS Safety of Pioglitazone Vs Placebo After Stroke or TIA PPT | NDEI